<DOC>
	<DOC>NCT00502671</DOC>
	<brief_summary>This single arm study will evaluate the safety profile of Xeloda as monotherapy for adjuvant treatment of colon cancer. All patients will receive Xeloda 1250mg/m2 p.o. twice daily as intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week without treatment). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; colon cancer (Dukes stage C); surgery, with no evidence of remaining tumor; ECOG performance status of &lt;=1. previous therapy for currently treated colon cancer; any evidence of metastatic disease; history of other malignancy within last 5 years; clinically significant cardiac disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>